NASDAQ:TLX Telix Pharmaceuticals Limited American Depositary Shares (TLX) Stock Price, News & Analysis $16.84 +0.24 (+1.45%) Closing price 04:00 PM EasternExtended Trading$16.84 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Telix Pharmaceuticals Limited American Depositary Shares Stock (NASDAQ:TLX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get TLX alerts:Sign Up Key Stats Today's Range$16.06▼$17.0150-Day Range$13.61▼$19.2252-Week Range$13.61▼$30.36Volume36,220 shsAverage Volume26,906 shsMarket Capitalization$5.69 billionP/E RatioN/ADividend YieldN/APrice Target$22.00Consensus RatingBuy Company OverviewTelix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.Read More… Receive TLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telix Pharmaceuticals Limited American Depositary Shares and its competitors with MarketBeat's FREE daily newsletter. Email Address TLX Stock News HeadlinesTelix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging EfficacyMay 7, 2025 | globenewswire.comTelix Pharmaceuticals Limited American Depositary Shares (TLX)May 1, 2025 | nasdaq.comWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington. May 27, 2025 | Altimetry (Ad)Telix's Illuccix PSMA-PET Imaging Agent Approved in FranceApril 28, 2025 | globenewswire.comTelix shares crash 8% on US FDA blowApril 27, 2025 | msn.comTelix Pharmaceuticals Ltd. ADRApril 23, 2025 | wsj.comTelix Reports US$186M Q1 Revenue, Up 62% YOYApril 22, 2025 | globenewswire.comIPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy CandidateApril 15, 2025 | globenewswire.comSee More Headlines TLX Stock Analysis - Frequently Asked Questions How have TLX shares performed this year? Telix Pharmaceuticals Limited American Depositary Shares' stock was trading at $15.40 at the beginning of the year. Since then, TLX stock has increased by 9.4% and is now trading at $16.84. View the best growth stocks for 2025 here. When did Telix Pharmaceuticals Limited American Depositary Shares IPO? Telix Pharmaceuticals Limited American Depositary Shares (TLX) raised $202 million in an initial public offering on Friday, June 14th 2024. The company issued 17,000,000 shares at a price of $11.87 per share. Who are Telix Pharmaceuticals Limited American Depositary Shares' major shareholders? Telix Pharmaceuticals Limited American Depositary Shares' top institutional investors include ABC Arbitrage SA (0.01%) and Private Advisor Group LLC. How do I buy shares of Telix Pharmaceuticals Limited American Depositary Shares? Shares of TLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today5/27/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TLX Previous SymbolNASDAQ:TLX CIK2007191 Webwww.telixpharma.com Phone61-3-9093-3855FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$22.00 High Stock Price Target$22.00 Low Stock Price Target$22.00 Potential Upside/Downside+32.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$783.21 million Price / Sales7.16 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares337,970,000Free FloatN/AMarket Cap$5.61 billion OptionableN/A BetaN/A (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:TLX) was last updated on 5/27/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telix Pharmaceuticals Limited American Depositary Shares Please log in to your account or sign up in order to add this asset to your watchlist. Share Telix Pharmaceuticals Limited American Depositary Shares With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.